Market Overview

The global cancer immunotherapy market was valued at USD 129.5 Billion in 2024 and is projected to reach USD 271.2 Billion by 2033, growing at a CAGR of 8.6% during 2025-2033. The market expansion is driven by the rising incidence of cancer cases worldwide, advances in treatment technologies like neoantigen-based vaccines and bispecific antibodies, and supportive regulatory environments facilitating faster drug approvals. North America dominates with a 45.2% market share, supported by favorable government initiatives and healthcare infrastructure.

Study Assumption Years

• Base Year: 2024
• Historical Year/Period: 2019-2024
• Forecast Year/Period: 2025-2033

Cancer Immunotherapy Market Key Takeaways

• Current Market Size: USD 129.5 Billion in 2024
• CAGR: 8.6% during 2025-2033
• Forecast Period: 2025-2033
• North America leads the market with over 45.2% share in 2024, driven by increasing cancer cases and government initiatives.
• Monoclonal antibodies dominate therapy types with approximately 71.2% market share in 2024.
• Lung cancer represents the largest application segment due to its high prevalence and immunotherapy adoption.
• Hospitals are the leading end-user segment with around 68.2% market share in 2024.
• Strategic collaborations among key pharmaceutical and research institutions are accelerating innovation.

Sample Request Link: https://www.imarcgroup.com/cancer-immunotherapy-market/requestsample

Market Growth Factors

The rising prevalence of cancer worldwide is a primary growth driver for the cancer immunotherapy market. According to the International Agency for Research on Cancer, approximately 19.29 million cancer cases were estimated in 2020, expected to rise to 24.58 million by 2030. This increase is fueling demand for more effective treatment options like immunotherapies. Data from GLOBOCAN for 2020 show 2,281,658 new cancer cases and 612,390 deaths in the United States alone. High-incidence cancers such as lung and breast cancer constitute a significant portion of these figures, underscoring the necessity for advanced therapies. Furthermore, the Canadian Cancer Society reported nearly 29,800 lung cancer diagnoses in 2020, accounting for 13% of new cases in Canada, with a high mortality rate of 21,200 deaths, illustrating an urgent need for efficacious treatments.

Significant investments in research and development (R&D) activities by market leaders are propelling the introduction of innovative cancer immunotherapies. As per the National Clinical Trials (NCT) Registry, more than 1,000 immune-based cancer therapy clinical trials were ongoing worldwide as of September 2020. Regulatory bodies in various countries are accelerating approval processes to support rapid adoption, exemplified by the FDA approval of Quizartinib (Vanflyta) in July 2023 for acute myeloid leukemia. Such regulatory facilitation is expected to bolster market growth by enabling quicker patient access to novel therapies.

Collaborations and partnerships between pharmaceutical companies and research institutions are vital growth enablers. Notable examples include the strategic collaboration between Immatics and Moderna in September 2023 for oncology therapeutics development, and the joint research project initiated by BioMed X and Ono Pharmaceutical in December 2023 to create next-generation immunotherapies. Additionally, the Partnership for Accelerating Cancer Therapies (PACT) public-private collaboration, funded with USD 220 million, aims to advance immune therapies with over 37 clinical trials and 4,000 planned participants across more than 15 cancer types. These alliances, complemented by mergers and acquisitions among leading companies like Amgen Inc., AstraZeneca plc, Bayer AG, and Eli Lilly and Company, are expected to substantially drive market expansion.

Market Segmentation

Analysis by Therapy Type:

• Monoclonal Antibodies: Represent the largest segment with about 71.2% market share in 2024, fueled by considerable funding in R&D and therapeutic advancements. The segment investigates treatment potentials across various cancer types, including FDA approval of Talvey for multiple myeloma.
• Cancer Vaccines: Not separately detailed in text; part of overall immunotherapy advancements.
• Checkpoint Inhibitors: Not separately detailed in text.
• Immunomodulators: Not separately detailed in text.
• Others: Not detailed.

Analysis by Application:

• Lung Cancer: Largest revenue share due to rising incidence and immunotherapy adoption, supported by product approvals like FDA's authorization of Augtyro for NSCLC.
• Breast Cancer: Mentioned as key cancer type; specific data not detailed.
• Colorectal Cancer: Mentioned; no additional details.
• Melanoma: Mentioned; no additional details.
• Prostate Cancer: Mentioned; no additional details.
• Head and Neck Cancer: Mentioned; new mRNA vaccine trials initiated for this type.
• Others: Not detailed.

Analysis by End User:

• Hospitals: Leading segment with around 68.2% market share in 2024, driven by increased cancer admissions and immunotherapy treatments.
• Cancer Research Centers: Mentioned; details not quantified.
• Clinics: Mentioned; details not quantified.
• Others: Not detailed.

Regional Insights

North America dominates the global cancer immunotherapy market with over 45.2% market share in 2024. Growth is propelled by rising cancer incidence, rapid bioinformatics advancements, and favorable government initiatives. The United States alone accounted for 92.70% of North America's market in 2024, with investments exceeding USD 7.22 billion in cancer research. Leading companies and robust clinical trial activities reinforce its market leadership. The U.S. national cancer plan and programs like Cancer Moonshot further stimulate industry innovation and access.

Recent Developments & News

• October 2024: FDA approved Bristol Myers Squibb’s Opdivo (nivolumab), a PD-1 inhibitor, for perioperative treatment of resectable NSCLC, demonstrating a 42% reduction in disease recurrence.
• September 2024: Amgen presented positive Phase 1b data for their DLL3-targeting BiTE molecule IMDELLTRA combined with PD-L1 inhibitors for extensive-stage small cell lung cancer.
• July 2024: AstraZeneca reported Phase III ADRIATIC trial results showing significant survival benefits of Imfinzi in limited-stage small cell lung cancer.
• December 2023: Oxford University Hospitals launched an mRNA cancer vaccine trial for head and neck cancers.
• December 2023: BioMed X and Ono Pharmaceutical announced collaboration to design neutrophil-based next-generation immunotherapies.

Key Players

• Amgen Inc
• AstraZeneca plc
• Bayer AG
• Bristol-Myers Squibb Company
• Eli Lilly and Company
• F. Hoffmann-La Roche Ltd
• GSK plc.
• Johnson & Johnson
• Merck & Co., Inc.
• Merck KGaA
• Novartis AG
• Pfizer Inc.
• Sanofi S.A

If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.

👉Get Custom Market Research for Your Business👈

About Us

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provides a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

Contact Us

IMARC Group

134 N 4th St. Brooklyn, NY 11249, USA

Email: sales@imarcgroup.com

Tel No: (D) +91 120 433 0800

United States: +1-201971-6302